...reproduction. Details of the open-label trial will be published in the Journal of Human Virology. The Immune Response Corp....

...human cell line engineered to express one or more antigens and one or more cytokines. The Immune Response Corp....

...of at least 20 percent from baseline, and improvements in three of five other criteria. The Immune Response Corp....

...readers of the white paper may have raised their eyebrows upon seeing the bankruptcy of Orchestra Therapeutics Inc....
...example of the biotech sector's woes brought on by the current economic climate. Orchestra (formerly The Immune Response Corp....

...Orchestra filed for Chapter 7 bankruptcy. Orchestra (formerly The Immune Response Corp. ) restructured and reduced headcount in April...
...in Phase IIb testing to treat relapsing-remitting multiple sclerosis (RRMS) (see BioCentury, April 9, 2007). Orchestra Therapeutics Inc....

...San Diego, Calif. Business: Dermatology Hired: Michael Green as CFO, formerly CFO and COO of Orchestra Therapeutics Inc....

...company said it would seek strategic alternatives for its HIV program (see BioCentury, April 9). Orchestra Therapeutics Inc....

...company said it would seek strategic alternatives for its HIV program (see BioCentury, April 9). Orchestra Therapeutics Inc....

...loss of $13.3 million. IMRP also will change its name to Orchestra Therapeutics Inc. effective April 16. The Immune Response Corp....

...IMRP started a placebo-controlled, double-blind, U.S. and European Phase IIb trial in 200 patients. The Immune Response Corp. (IMRP...